Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metastatic carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,713 result(s) found for: Metastatic carcinoma. Displaying page 1 of 136.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000781-23 Sponsor Protocol Number: GEN207 Start Date*: 2008-06-09
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi...
    Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023860 Laryngeal squamous cell carcinoma stage III LLT
    9.1 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001951-20 Sponsor Protocol Number: UCL/06/053 Start Date*: 2008-03-12
    Sponsor Name:University College London
    Full Title: A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Locally advanced or metastatic squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063569 Metastatic squamous cell carcinoma LLT
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007045-12 Sponsor Protocol Number: PV RCC 07-01 Start Date*: 2008-02-21
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines ...
    Medical condition: renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003833-24 Sponsor Protocol Number: AGMT_HNO_PN Start Date*: 2016-06-30
    Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin
    Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10031117 Oropharyngeal squamous cell carcinoma stage III LLT
    20.0 100000004864 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    20.0 100000004864 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    20.0 100000004864 10031103 Oropharyngeal cancer stage unspecified LLT
    20.0 100000004864 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    20.0 100000004864 10023860 Laryngeal squamous cell carcinoma stage III LLT
    20.0 100000004864 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    20.0 100000004864 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000928-71 Sponsor Protocol Number: GOIRC02/2008-TWIST Start Date*: 2008-11-14
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008
    Medical condition: Patients with advanced non-clear Cell Renal Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    9.1 10038458 Renal granular cell carcinoma PT
    9.1 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002300-40 Sponsor Protocol Number: LARA4 Start Date*: 2020-12-18
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title:
    Medical condition: ADVANCED UTERINE CERVICAL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004380-40 Sponsor Protocol Number: CA209-76U Start Date*: 2020-11-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab
    Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004548-35 Sponsor Protocol Number: 15081982 Start Date*: 2010-08-20
    Sponsor Name:Radboud university nijmegen medical centre
    Full Title: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
    Medical condition: Patients with metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002941-12 Sponsor Protocol Number: INCMGA0012-203 Start Date*: 2019-06-19
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed diagnosis of : a. NSCLC with high PD-L1 expression (TPS ≥ 50%) and no EGFR, ALK, or ROS activating genomic tumor ab...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    21.0 100000004864 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005976-15 Sponsor Protocol Number: CCR3024 Start Date*: 2008-03-27
    Sponsor Name:Royal Marsden Hospital NHS Trust
    Full Title: A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer ...
    Medical condition: Advanced (Inoperable locally advanced, metastatic or recurrent) , histologically verified adenocarcinoma or undifferentiated carcinoma of the oesophagus, oesophagogastric junction or stomach.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017770 Gastric carcinoma LLT
    9.1 10030155 Oesophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002957-67 Sponsor Protocol Number: CA209-010 Start Date*: 2011-11-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic T...
    Medical condition: Advanced/Metastatic renal cell carcinoma with a clear cell component
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038410 Renal cell carcinoma recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020447-13 Sponsor Protocol Number: CRAD001L2404 Start Date*: 2012-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002556-41 Sponsor Protocol Number: TRX 1.0 Start Date*: 2008-02-07
    Sponsor Name:Trimed Biotech GmbH
    Full Title: A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001116-22 Sponsor Protocol Number: 0646-004 Start Date*: 2007-10-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer
    Medical condition: metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010036 Colorectal carcinoma LLT
    9.1 10027477 Metastatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) SE (Completed) LT (Completed) FI (Completed) FR (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004236-40 Sponsor Protocol Number: I1-GOA-1 Start Date*: 2007-12-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
    Medical condition: advanced metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003606-53 Sponsor Protocol Number: CA224106 Start Date*: 2022-06-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocell...
    Medical condition: Advanced/metastatic hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-008478-30 Sponsor Protocol Number: RWZB-09/1 Start Date*: 2009-05-26
    Sponsor Name:Lukaskrankenhaus GmbH
    Full Title: [Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus] Target-specific therapy of metastatic urothelial carcinoma with temsirolimus
    Medical condition: Chemotherapy refractory metastatic urothelia carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017054-12 Sponsor Protocol Number: 1775-008 Start Date*: 2010-05-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer
    Medical condition: Patients with advanced, metastatic, and recurrent carcinoma of the uterine cervix
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012010-52 Sponsor Protocol Number: mRCC Start Date*: 2009-08-04
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma
    Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 02 01:55:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA